A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers

British Journal of Clinical Pharmacology

Volumn 66, Issue 4, 2008, Pages 508-516

  Schöller Gyüre, Monika ^a   Kakuda, Thomas N ^b   De Smedt, Goedele ^a   Vanaken, Hilde ^a   Bouche, Marie Paule ^c   Peeters, Monika ^a   Woodfall, Brian ^a   Hoetelmans, Richard M W ^a  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec Inc   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Drug drug interaction; Etravirine; Non nucleoside reverse transcriptase inhibitor; Omeprazole; Ranitidine; TMC125

Indexed keywords

CYTOCHROME P450 2C; CYTOCHROME P450 2C19; CYTOCHROME P450 3A; DRUG METABOLITE; ETRAVIRINE; OMEPRAZOLE; RANITIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH PH; TREATMENT INDICATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTI-ULCER AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG INTERACTIONS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; PYRIDAZINES; RANITIDINE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 51649083570     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03214.x     Document Type: Article

References (44)

1. Béïque L, Giguère P, la Porte C, Angel J. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med 2007 8: 335 45.
2. Van Lunzen J, Liess H, Arasteh K, Walli R, Daut B, Schürmann D. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy. HIV Med 2007 8: 220 5.
3. Luber A, Garg V, Gharakhanian S, Vertex HIV Program Team. Survey of medication used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2004 [Abstract 206
4. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006 29: 769 84.
5. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001 13: 611 6.
6. Luber AD, Brower R, Kim D, Silverman R, Peloquin CA, Frank I. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med 2007 8: 457 64.
7. Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetic effect of omeprazole on atazanavir with ritonavir in healthy subjects. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 Abstract
8. Tappouni HL, Rublein JC, Donovan BJ, Hollowell SB, Tien HC, Min SS, Theodore D, Rezk NL, Smith PC, Tallman MN, Raasch RH, Kashuba AD. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm 2008 65: 422 8.
9. Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob Agents Chemother 2005 49: 467 9.
10. Sekar VJ, Lefebvre E, De Paepe E, De Marez T, De Pauw M, Parys W, Hoetelmans RMW. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother 2007 51: 958 61.
11. La Porte CJL, Cameron DW, Sabo JP, Murray GE, Fagan N, Bosisio M, Jones P, De Perri G. The effect of omeprazole, food and formulation on the pharmacokinetics of tipranavir coadministered with ritonavir (TPV/r). 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, Hungary, April 2007 [Abstract 59 ]
12. Klein C, Chiu YL, Cai Y, Beck K, King K, Causemaker S, Doan T, Esslinger HU, Podsadecki T, Hanna G. Lack of effect of acid reducing agents on the pharmacokinetics of lopinavir/ritonavir tablet. 13th CROI. Denver, CO, February 2006 [Abstract 578]
13. Overton ET, Tschampa J, Klebert M, Rodriguez M, Spitz T, Kim G, Mondy K, Acosta E. Acid reduction with a proton pump inhibitor does not effect pharmacokinetics of lopinavir or ritonavir in HIV-infected subjects on lopinavir/ritonavir-based therapy. 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, Hungary, April 2007 [Abstract 60]
14. Chiu YL, Klein CE, Woodward WC, King KR, Naylor C, Awni W, Brun S. Lack of effect gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients. AIDS Patient Care STDS 2007 21: 247 51.
15. Winston A, Back D, Fletcher C, Robinson L, Unsworth J, Tolowinska I, Schutz M, Pozniak AL, Gazzard B, Boffito M. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS 2006 20: 1401 6.
16. Singh K, Dickinson L, Chaikan A, Back D, Fletcher C, Pozniak A, Moyle G, Nelson M, Gazzard B, Herath D, Boffito M. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther 2007 Sep 26 [E pub ahead of print], PMID: 17898705.
17. 2, CYP2D6 and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 1999 65: 369 76.
18. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolisers of omeprazole. Clin Pharmacol Ther 1990 47: 79 85.
19. Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, Horai Y, Tomono Y, Yamato C, Toyoki T. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′hydroxylation. Clin Pharmacol Ther 1995 58: 155 64.
20. Blohme I, Idström JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol 1993 35: 156 60.
21. Caraco Y, Wilkinson GR, Wood AJJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996 60: 396 404.
22. Lemahieu PD, Maes BD, Verbeke K, Vanrenterghem Y. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney Int 2005 67: 1152 60.
23. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Bethune MP. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004 48: 4680 6.
24. Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, Andries K, Pauwels R, de Bethune MP. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005 79: 12773 82.
25. Cohen C, Steinhart CR, Ward DJ, Ruane P, Vingerhoets J, Peeters M, White A, Baeten B, de Bethune M, Woodfall B. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. 16th International AIDS Conference. Toronto, Canada, 2006 [Abstract TUPE0061]
26. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, De Smedt G, Leopold L, Trefiglio R, Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 370: 29 38.
27. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, De Smedt G, Baeten B, Beets G, Sinha R, Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 370: 39 48.
28. Haubrich R, Cahn P, Grinsztejn B, Lalezari J, Madruga J, Mills A, Peeters M, Vingerhoets J, Iveson K, De Smedt G. DUET-1: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 612 treatment-experienced HIV-1 infected patients. 15th CROI. Boston, MA, February 2008 [Poster 790
29. Johnson M, Campbell T, Clotet B, Katlama C, Lazzarin A, Towner W, Peeters M, Vingerhoets J, Bollen S, De Smedt G. DUET-1: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 591 treatment-experienced HIV-1 infected patients. 15th CROI. Boston, MA, February 2008 [Poster 791
30. Schöller-Gyüre M, Raoof A, Mannens G, Lachau-Durand S, Woodfall B, Peeters M, Vyncke V, Vandermeulen K, Hoetelmans RM. Mass-balance of 14C-labelled TMC125 in healthy volunteers. 8th International Workshop of Clinical Pharmacology. Budapest, Hungary, April 2006 [Abstract 78
31. Kakuda TN, Schöller-Gyüre M, Woodfall BJ, De Smedt G, Peeters M, Vandermeulen K, Hoetelmans R. TMC125 in combination with other medications: summary of drug-drug interactions. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2006 [Abstract PL5.2
32. Schöller-Gyüre M, Leemans R, Vyncke V, Vandermeulen K, Peeters M, Baeten B, Debroye C, Woodfall B, Hoetelmans R. Effect of food on the oral bioavailability of the phase III formulation of TMC125. 7th International Workshop of Clinical Pharmacology. Lisbon, Portugal, April 2006 [Abstract 80
33. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995 12: 413 20.
34. Schöller M, Hoetelmans R, Beets G, Vandermeulen K, Peeters M, Bastiaanse L, Leemans R, Debroye C, Woodfall B. Substantial improvement of oral bioavailability of TMC125 using new tablet formulations in healthy volunteers. 6th International Workshop of Clinical Pharmacology. Quebec, Canada, April 2005 [Abstract 6.8
35. Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996 60: 157 67.
36. Ley LM, Becker A, Lühmann R, Sander P, Lücker PW. Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine. Methods Find Exp Clin Pharmacol 2005 27: 25 9.
37. Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997 19: 1013 23.
38. Lachmann L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000 95: 57 61.
39. Komazawa Y, Adachi K, Mihara T, Ono M, Kawamura A, Fujishiro H, Kinoshita Y. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol 2003 18: 678 82.
40. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lanzoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001 346: 551 7.
41. Tougas G, Earnest DL, Chen Y, Vanderkoy C, Rojavin M. Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod. Aliment Pharmacol Ther 2005 22: 59 65.
42. Fleisher D, Li C, Zhou Y, Pao L, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet 1999 36: 233 54.
43. Kakuda TN, Schöller-Gyüre M, Peeters M, Vingerhoets J, Corbett C, Woodfall BJ, Hoetelmans RM. Pharmacokinetics and pharmacodynamics of TMC125 in HIV-infected patients with non-nucleoside reverse transcriptase inhibitor and protease inhibitor resistance: TMC125-C223. 14th CROI. Los Angeles, CA, February 2007 [Abstract L-131
44. Kakuda TN, Wade JR, Snoek E, Peeters M, Corbett C, De Smedt G, Leopold L, Vingerhoets J, Woodfall B, Hoetelmans RM. Pharmacokinetics (PK) and pharmacodynamics (PD) of the non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 in treatment-experienced HIV-1 infected patients: pooled 24-week results of DUET-1 and DUET-2. 15th CROI. February. Boston, MA, 2008 [Abstract L-160 ].